CUPRIC GLYCINATE MONOHYDRATE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C2H4NO2.Cu.H2O
Molecular Weight	229.679
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CUPRIC GLYCINATE MONOHYDRATE

Structure Search

SMILES

O.[Cu++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=IBCBKVAHJPKRLA-UHFFFAOYSA-L

InChI=1S/2C2H5NO2.Cu.H2O/c2*3-1-2(4)5;;/h2*1,3H2,(H,4,5);;1H2/q;;+2;/p-2

HIDE SMILES / InChI

Molecular Formula	Cu
Molecular Weight	63.546
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C2H5NO2
Molecular Weight	75.0666
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Xanthine dehydrogenase/oxidase 41 Target ID: CHEMBL1075246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3861140	Inhibitor 8297	3.42 µM [Ki]
Ceruloplasmin 35 Target ID: P00450 Gene ID: 1356.0 Gene Symbol: CP Target Organism: Homo sapiens (Human) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Binding Agent 1064
Glutathione S-transferase, rat, liver 35 Target ID: Glutathione S-transferase, rat, liver Sources: https://www.ncbi.nlm.nih.gov/pubmed/3008276	Binding Agent 1064
reactive oxygen species metabolic process 68 Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8503093	Modulator 828
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22098250	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Root caries 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8556785 https://www.ncbi.nlm.nih.gov/pubmed/3201109	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22444781 https://www.ncbi.nlm.nih.gov/pubmed/20569928	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518	Preventing	Approved 8429	Cupric glycinate Approved Use Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Unknown 2578
Copper deficiency 35 Sources: http://www.bayeranimal.co.nz/en/product-detail.php?p=%203030	Primary	Approved 8429	COPPER•MAX Approved Use Unknown
Unknown 2578
Menkes' kinky hair disease 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6520571 https://www.ncbi.nlm.nih.gov/pubmed/4042823 https://www.ncbi.nlm.nih.gov/pubmed/189959	Primary	Not Provided 504	Unknown Approved Use Unknown
Liver cancer 53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6526221 https://www.ncbi.nlm.nih.gov/pubmed/7326825	Preventing	Preclinical	Unknown Approved Use Unknown
Unknown 2578
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21039194	Primary	Preclinical	Unknown Approved Use Unknown
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22812694	Diagnostic	Preclinical	Unknown Approved Use Unknown
Unknown 2578
Copper deficiency 35 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Preventing	Approved 8429	COPPER Approved Use Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Unknown 2578
Unknown 2578
Copper deficiency 35 Sources: http://www.noahcompendium.co.uk/?id=-446109	Preventing	Approved 8429	COPINOX Approved Use Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.

PubMed

Title	Date	PubMed
Determination of protein by the biuret reaction using cupric hydroxide suspension reagent.	1960	14446699
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers.	2000 Jul	10873882
Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells.	2009 Oct	19699289
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.	2009 Oct 30	19683516
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.	2010 May 19	20171267
Zinc prevents the copper-induced damage of cultured astrocytes.	2010 Oct	20600438
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.	2011 Apr	21281096
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.	2011 Dec 27	22077320
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.	2013 Jan 18	23301994
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.	2013 May	23589377
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts.	2014	25336953
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.	2014	24343273
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.	2014 Feb 26	24106015
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.	2014 Jul	24815816
Electron induced surface reactions of organometallic metal(hfac)₂ precursors and deposit purification.	2014 Jun 11	24784352
Dissecting copper homeostasis in diabetes mellitus.	2017 Apr	28276155
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.	2017 Apr 1	28378716
Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities.	2017 Feb	28007539
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.	2017 Jul	28478000
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.	2017 Jun	27899044

Patents

Sample Use Guides

In Vivo Use Guide

Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Route of Administration: Intravenous

In Vitro Use Guide

Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:58:38 UTC 2023` Edited by `admin` on `Fri Dec 15 15:58:38 UTC 2023`
Record UNII	163J4O4DFH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CUPRIC GLYCINATE MONOHYDRATE

Common Name

English

COPPER, BIS(GLYCINATO-.KAPPA.N,.KAPPA.O)-, MONOHYDRATE

Common Name

English

COPPER, BIS(GLYCINATO-N,O)-, MONOHYDRATE

Common Name

English

COPPER, BIS(GLYCINATO)-, MONOHYDRATE

Common Name

English

COPPER, BIS(GLYCINATO-.KAPPA.N,.KAPPA.O)-, HYDRATE (1:1)

Common Name

English

CUPRIC GLYCINATE HYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

163J4O4DFH

Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023

PRIMARY

PUBCHEM

71587023

Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023

PRIMARY

EPA CompTox

DTXSID20171302

Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023

PRIMARY

CAS

18253-80-0

Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023

PRIMARY

Related Record Type Details


					8CBV67279L

CUPRIC CATION

PARENT -> SALT/SOLVATE


					TE7660XO1C

Glycine

PARENT -> SALT/SOLVATE


					68VAV8QID7

CUPRIC GLYCINATE

ANHYDROUS->SOLVATE

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides